Bold headline: Wegovy remains out of Canada’s public drug plans as negotiations collapse.
Negotiations that could have made Wegovy, a weight‑loss medication from Novo Nordisk, eligible for Canada’s public health coverage have ended without an agreement. Novo Nordisk, the Danish company behind Wegovy, had been approached about negotiating a lower price to secure reimbursement through Canada’s public system.
Canada’s Drug Agency (an independent body that evaluates the cost-effectiveness of medications) requested talks through the pan‑Canadian Pharmaceutical Alliance, which negotiates prices for drugs on behalf of federal, provincial, and territorial governments. The pan‑Canadian Pharmaceutical Alliance stated on its site that the negotiations concluded without agreement because the manufacturer declined to negotiate.
The Drug Agency released a July recommendation indicating Wegovy’s list price would be about $5,066 per patient per year, based on a maintenance dose of 2.4 mg weekly for weight management — roughly $400 per month. Novo Nordisk confirmed it has not pursued public reimbursement at this time, while reiterating its commitment to sustaining Canadians’ access to obesity medications and future innovations.
The pan‑Canadian Pharmaceutical Alliance said Novo Nordisk declined their October negotiation request, with no offers exchanged, and the file is closed. They added they’re open to re‑engagement if Novo Nordisk changes its position or submits an unsolicited offer.
The Drug Agency recommended Wegovy could be eligible for public reimbursement under chronic weight management if certain conditions are met. Eligible patients would typically have a BMI of at least 27 kg/m² and a pre‑existing cardiovascular disease, including conditions involving narrowed arteries that reduce blood flow to the heart, brain, or limbs.
For Wegovy to qualify for coverage, the Drug Agency stressed the need for concurrent lifestyle interventions: a reduced‑calorie diet and increased physical activity, alongside a reduced drug price. They also noted the drug does not represent good value at the current public list price, based on health‑economics assessments, and a price reduction would be necessary.
Projecting costs for public drug plans, the Drug Agency estimated Wegovy could total up to $600 million over three years at current demand, with potential growth to $3.5 billion if uptake accelerates.
Advocates weigh in with mixed views. Ian Patton of Obesity Canada emphasizes that weight‑loss medications aren’t a universal cure, yet they can be life‑changing for many people. He cautions that in the absence of coverage, access remains limited for the majority who could benefit.
Patton also notes that semaglutide-based medicines, including Wegovy, Ozempic, and Zepbound, are approved in Canada under certain conditions, but public funding remains the hurdle. He remains hopeful that forthcoming generic options could provide more affordable choices for Canadians.
Meanwhile, the U.S. has taken steps to reduce prices for these treatments through Medicare and Medicaid, signaling a contrast in health‑policy approaches between neighboring countries.
What do you think: should publicly funded coverage for weight‑loss medications be expanded despite high upfront costs, given their potential long‑term health benefits? Are there alternative models (tiered pricing, risk‑sharing, or targeted eligibility) that could improve access while preserving system sustainability?
